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Caster Semenya and the Policing of Competitive
Athletic Advantage
TAYLOR VANN
In recent years, transgender and intersex athletes competing in track and field
have come under intense scrutiny. The most notable of these athletes at the elite
level is Caster Semenya of South Africa. Semenya has been accused of benefiting
from an unfair competitive advantage due to her natural biological makeup. In
response, international track and field’s governing body has promulgated multiple
regulations to address athletes like Semenya. This article examines these
regulations and their impact on transgender and intersex athletes at multiple levels
of competition, It argues that these regulations and similar attempts under Title IX
in the United States are fundamentally flawed because they attempt to create a level
playing field when, in reality, success in track and field, like most other sports, is
and always has been dependent on differences in natural abilities. These regulations
and policies are revealed to be inadequate because they proceed based on a flawed
perception of what is considered a fair competitive advantage.
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Caster Semenya and the Policing of Competitive
Athletic Advantage
TAYLOR VANN *
INTRODUCTION
When Caster Semenya stepped onto the track in Berlin, Germany at the
2009 International Association of Athletics Federations (“IAAF”) World
Championships, she may very well have known that in less than two
minutes, her life was about to change forever. From the moment the starting
gun was fired, there was no doubt who would stand atop the podium.
Semenya finished in first place in a world-leading time of 1 minute, 55.45
seconds, more than two seconds ahead of the second-place finisher.1 Even
before the race began, however, there was controversy surrounding
Semenya’s presence at the year’s most competitive track and field competition.
On the day of the 800-meter final, the IAAF confirmed that it had
required Semenya to submit to sex determination testing.2 When asked why,
Pierre Weiss, the general secretary of the IAAF, stated that the testing was
due to “ambiguity, not because we believe she is cheating.” 3 That initial
testing because of “ambiguity” resulted in nearly one year of review by a
medical panel convened by the IAAF, during which time Semenya was
barred from competing in international competitions.4 The panel ultimately
determined that Semenya had a condition called hyperandrogenism, which
naturally caused her to have elevated levels of testosterone in her body.5 She
was nonetheless permitted to compete in the 800-meter final6 and cement
herself as a world class middle-distance athlete.

*
University of Connecticut School of Law, J.D. 2021; Vassar College, B.A. 2016. Thank you to
my parents for fostering my love of sports. The amount of nights and weekends they sacrificed cannot
be understated. Special thank you to my colleagues at the Connecticut Law Review for their editorial
guidance.
1
800 Metres Result, 12th IAAF World Championships in Athletics, IAAF, https://www.worldathl
etics.org/results/iaaf-world-championships-in-athletics/2009/12th-iaaf-world-championships-in-athletic
s-3658/women/800-metres/final/result (last visited Jan. 7, 2021).
2
Christopher Clarey, Gender Test After a Gold-Medal Finish, N.Y. TIMES (Aug. 19, 2009),
https://www.nytimes.com/2009/08/20/sports/20runner.html.
3
Id.
4
Anna Kessel, Caster Semenya May Return to Track this Month After IAAF Clearance, GUARDIAN
(July 6, 2010, 2:03 PM), https://www.theguardian.com/sport/2010/jul/06/caster-semenya-iaaf-clearance.
5
Id.; What Are the Issues Behind the Court of Arbitration for Sport Ruling in Caster Semenya
Case?, WASH. POST (May 1, 2019, 6:37 AM), https://www.washingtonpost.com/sports/2019/05/01/wh
at-are-issues-behind-cas-ruling-caster-semenya-case/.
6
Clarey, supra note 2.
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Immediately following the 2009 IAAF final, Semenya was not allowed
to participate in the customary press conference following her world
championship victory, as officials deemed it “too much to ask” for an
eighteen-year-old to be peppered with questions from reporters regarding
the complex issue of gender and participation in professional athletics.7
However, Semenya likely would have been able to field these questions ably
if she had been allowed to do so. The 2009 World Championships were not
the first time her presence in women’s track and field generated
controversy.8 Since she first began competing in track and field as a child
growing up in rural South Africa, her success on the track generated
controversy.9 She faced years of scrutiny from competition officials, as well
as discriminatory and hostile statements from her fellow competitors.10
Thus, when she burst onto the international scene in 2009, questions
regarding her gender were not unexpected.
In the ensuing years since Semenya first became a world champion, she
has asserted herself as one of the most dominant middle-distance runners in
history. She went on to win gold in the 800 meters at both the 2011 and 2017
World Championships, as well as in the 2012 and 2016 Olympic Games. 11
Concurrent with Semenya’s unrivaled success, the IAAF has repeatedly
attempted to develop regulations to prevent Semenya and others with
hyperandrogenism from benefitting from what it deemed to be an unfair
competitive advantage.12 However, the IAAF repeatedly failed to develop
workable regulations that are suitable to all parties involved.13 This process
of trial and error in regulating the participation of intersex athletes has been
to the direct detriment of Semenya. At present, she is currently barred from
competing in IAAF events after having lost the final appeal of her challenge
to the IAAF’s most recent intersex athlete policy in 2020.14 Caster Semenya
7

Id.
Anna Kessel, Caster Semenya Wins 800m Gold but Cannot Escape Gender Controversy,
GUARDIAN (Aug. 19, 2009, 6:11 PM), https://www.theguardian.com/sport/2009/aug/19/caster-semenya800m-world-athletics-championships-gender.
9
Christopher Clarey, As Semenya Returns, So Do Questions, N.Y. TIMES (Aug. 22, 2010),
https://nytimes.com/2010/08/23/sports/23iht-TRACK.html.
10
Id.
11
Athlete Profile: Caster Semenya, WORLD ATHLETICS, http://worldathletics.org/athletes/southafrica/caster-semenya-242560 (last visited Jan. 7, 2021).
12
See How the Caster Semenya Controversy Has Unfolded Since 2009—A Timeline, GUARDIAN
(May 1, 2019, 6:06 AM), https://www.theguardian.com/sport/2019/may/01/how-caster-semenyacontroversy-unfolded-since-2009-timeline (providing a timeline of Semenya’s case and resulting IAAF
hyperandrogenism regulations).
13
See Int’l Ass’n of Athletics Fed’ns, IAAF Regulations Governing Eligibility of Females with
Hyperandrogenism to Compete in Women’s Competition § 1.1 (May 1, 2011) [hereinafter
Hyperandrogenism Regulations] (regulating the participation of intersex females beginning in 2011);
Int’l Ass’n of Athletics Fed’ns, Eligibility Regulations for the Female Classification (Athletes with
Differences of Sex Development) §§ 1.1(a)–(c) (Nov. 1, 2018) [hereinafter DSD Regulations] (regulating
the participation of intersex females from 2018 to present day).
14
Semenya v. Int’l Ass’n of Athletics Fed’ns, CAS 2018/O/5794, paras. 620, 626 (Court of
Arbitration for Sport, 2018); Jeré Longman, Track’s Caster Semenya Loses Appeal to Defend 800-Meter
8
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provides a valuable case study of the law and ethics surrounding elite
athletes who have intersex conditions. Her pursuit of inclusion and equality
has raised a question that goes to the heart of competitive athletics: Why are
some natural competitive advantages permissible when others are not?
A. History of Athletes Whose Genetic Backgrounds Provided Competitive
Advantages
The history of international and Olympic sports is replete with athletes
who succeeded in large part because they had genetic gifts that made them
perfectly suited for their chosen sport. Take, for example, Eero Mäntyranta
of Finland, who won seven medals in cross-country skiing, including three
gold, at the Winter Olympic Games in 1960, 1964, and 1968.15 It was not
until after his illustrious career concluded that Mäntyranta discovered he had
a rare genetic condition that caused his body to produce 65% more red blood
cells than the average male adult.16 For an endurance athlete, increased blood
oxygen levels makes all the difference. Consider also Donald Thomas, who
cleared 7’ 3.25” in the high jump on only the seventh attempt of his life. 17
Less than a year later, Thomas became a world champion high jumper.18 His
competitive advantage was also genetic—his legs and, in particular, his
Achilles tendons, were abnormally long for his body. 19 These genetic gifts
instantly made him a world class high jumper, despite having virtually no
prior training.20
An assessment of genetically gifted athletes would not be complete
without mention of Michael Phelps, the most decorated Olympian of all
time. Phelps has double-jointed ankles that allow for a greater range on his
kicks, a disproportionately large wingspan, and a metabolic system that
produces half the lactic acid of a typical elite swimmer.21 Low lactic acid
production is especially advantageous for endurance athletes, similar to the
high oxygen levels from which Mäntyranta benefited.22 All of these genetic
gifts combined to give Phelps the perfect body for swimming. Phelps retired
Title, N.Y. TIMES (Sep. 8, 2020), https://www.nytimes.com/2020/09/08/sports/olympics/caster-semeny
a-court-ruling.html.
15
Malcolm Gladwell, Man and Superman: In Athletic Competitions, What Qualifies as a Sporting
Chance?, NEW YORKER (Sept. 2, 2013), https://www.newyorker.com/magazine/2013/09/09/man-andsuperman.
16
Id.
17
Id.
18
Id.; Donald Thomas, ESPN, http://www.espn.com/olympics/summer08/fanguide/athlete?athlete
=97487 (last visited Jan 3, 2021).
19
Gladwell, supra note 15.
20
Id.
21
Monica Hesse, We Celebrated Michael Phelps’s Genetic Differences. Why Punish Caster
Semenya for Hers?, WASH. POST (May 2, 2019, 10:23 AM), https://www.washingtonpost.com/lifestyle
/style/we-celebrated-michael-phelpss-genetic-differences-why-punish-caster-semenya-forhers/2019/05/02/93d08c8c-6c2b-11e9-be3a-33217240a539_story.html.
22
Id.; Gladwell, supra note 15.
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from swimming after the 2016 Olympics in Rio De Janeiro, after having won
twenty-three gold medals, three silvers, and two bronzes.23
What is noteworthy about these athletes and many like them is that their
success on the international stage was met with virtually no opposition.24
They were not targeted by claims that they had unfair competitive
advantages. What, then, is the difference between athletes like Michael
Phelps and Caster Semenya?25
Semenya’s hyperandrogenism gives her a competitive advantage
because increased testosterone levels promote greater muscle growth 26—
which is certainly advantageous for a middle-distance runner trying to build
lean muscle in her legs, just like low lactic acid production is advantageous
for a swimmer. The end result for both Semenya and Phelps is that their
bodies enable them to outrace and outlast their competitors. However, the
governing body of Semenya’s sport has determined that she has an unfair
competitive advantage.
The difference between Caster Semenya and athletes like Michael
Phelps, this Note argues, is that her particular competitive advantage brings
her into conflict with part of the fundamental structure of her sport: that men
and women must compete separate from one another in order for there to be
fair competition. Different testosterone levels are considered a main
differentiator between biological males and females writ large, whereas
lactic acid production or blood oxygen retention is not. Therefore, Semenya
stands alone in that her particular natural advantage conflicts with the
fundamental male-female division of most competitive sports. As such, the
IAAF has deemed it necessary to prevent Semenya and those like her from
competing, as a means of preserving the overall integrity of the sport.
This Note discusses the history of attempts by professional track and
field’s regulatory body to prevent Caster Semenya and intersex athletes like
her from competing.27 It then juxtaposes the legal analysis used in her

23

Michael Phelps, OLYMPICS, https://www.olympic.org/michael-phelps (last visited Jan. 8, 2021).
Emily J. Cooper, Gender Testing in Athletic Competitions—Human Rights Violations: Why
Michael Phelps Is Praised and Caster Semenya Is Chastised, 14 J. GENDER, RACE & JUST. 233, 233–35
(2010).
25
Id. at 235; see also Shawn M. Crincoli, You Can Only Race If You Can’t Win? The Curious Cases
of Oscar Pistorius & Caster Semenya, 12 TEX. REV. ENT. & SPORTS L. 133, 139–40 (2011) (juxtaposing
the different treatment of Caster Semenya and Oscar Pistorius, a South African double-amputee sprinter
who, before being imprisoned for the murder of his girlfriend, was permitted to compete in regular
competitions despite using prosthetic legs that likely gave him a competitive advantage).
26
Testosterone—What It Does and Doesn’t Do, HARV. MED. SCH. (Aug. 29, 2019),
https://www.health.harvard.edu/drugs-and-medications/testosterone--what-it-does-and-doesnt-do.
27
See JOANNA HARPER, SPORTING GENDER: THE HISTORY, SCIENCE, AND STORIES OF
TRANSGENDER AND INTERSEX ATHLETES 2, 6–8 (2020), for a detailed historical account of female
athletics in the time of the ancient Greek Olympic Games, up through and including the advent of the
modern Olympics at the turn of the nineteenth century. Indeed, when the slate of female-contested events
at the Olympics were expanded beyond a few, short-distance races, there was speculation regarding the
gender identity of some of the athletes competing in those events: “The 1930s would include substantial
24
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challenges thus far with American equal protection jurisprudence in order to
demonstrate the unique challenge of ensuring that intersex, transgender, and
other gender nonconforming athletes are given equal opportunities to
compete at the highest levels of athletics.
I. BACKGROUND
A. Intersex Athletes
The term “intersex” broadly describes a variety of conditions relating to
a person’s reproductive or sexual anatomy.28 One “working” definition of
intersexuality is as follows: “a physical and/or chromosomal set of
possibilities in which the features usually understood as belonging distinctly
to either the male or female sex are combined in a single body.”29 As a
general matter, these conditions are such that the individual no longer fits
clearly within the traditional definitions of female or male.30 For example,
Caster Semenya’s specific condition has not been disclosed, but the results
of her testing indicate that she has hyperandrogenism, meaning she has
heightened testosterone levels that place her in the lower end of the average
range for males.31 Aside from hyperandrogenism, there are numerous other
conditions that would cause a person to be considered intersex.32 Regardless
of the specific physiological characteristics of the individual, being intersex,
like gender identity, is largely a socially constructed category that brings
with it stereotypes and difficulties assimilating into society.33
Aside from Caster Semenya, other intersex athletes have competed and
will continue to compete in professional sports.34 Most notable in track and
field is Dutee Chand, who, like Semenya, has hyperandrogenism.35 Chand
growth of women’s sport; however, that decade would also be the first in which the femininity of many
women competitors would be called into question . . . .” Id. at 8.
28
What is Intersex?, INTERSEX SOC’Y OF N. AM., https://isna.org/faq/what_is_intersex/ (last visited
Jan. 6, 2021).
29
Ilana Gelfman, Because of Intersex: Intersexuality, Title VII, and the Reality of Discrimination
“Because of . . . [Perceived] Sex”, 34 N.Y.U. REV. L. & SOC. CHANGE 55, 57 (2010) (emphasis omitted)
(quoting MORGAN HOLMES, INTERSEX: A PERILOUS DIFFERENCE 32 (2008)).
30
Cooper, supra note 24, at 238–39.
31
Jeré Longman, Understanding the Controversy over Caster Semenya, N.Y. TIMES (Aug. 18,
2016), https://www.nytimes.com/2016/08/20/sports/caster-semenya-800-meters.html. Since Semenya
first came onto the international scene in 2009, there have been unverified reports that she was afflicted
with other conditions, such as possessing internal testes and having testosterone levels three times that
of average women. Id.
32
See Gelfman, supra note 29, at 56–57 (discussing other intersex conditions, such as Partial
Androgen Insensitivity Syndrome, Congenital Adrenal Hyperplasia, and Klinefelter’s Syndrome).
33
Cooper, supra note 24, at 237–39.
34
Jessica L. Adair, In a League of Their Own: The Case for Intersex Athletes, 18 SPORTS LAWS. J.
121, 135–36 (2011) (discussing the careers of Polish sprinter Eva Klobukowska and Spanish hurdler
María José Martínez-Patiño).
35
Juliet Macur, Fighting for the Body She Was Born With, N.Y. TIMES (Oct. 6, 2014),
https://www.nytimes.com/2014/10/07/sports/sprinter-dutee-chand-fights-ban-over-her-testosteronelevel.html.
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played a central role in the IAAF’s development of its hyperandrogenism
regulations that Semenya would eventually challenge in 2018. With her
diminutive stature (four feet and eleven inches tall)36 and impoverished
upbringing as the child of parents who made “less than $8 a week as
weavers” in Odisha, India,37 Chand would not have been expected to become
India’s most promising young sprinter. Nonetheless, she gained recognition
as a teenager when she won multiple national titles while competing in the
junior division.38 Her unexpected success continued on the international stage,
where she won gold in both the 200 meters and as a member of the 4x400
meter sprint relay at the 2014 Asian Junior Track and Field Championships.39
Similar to Semenya, Chand’s success brought increased attention from the
IAAF. During the 2014 season, she was asked by representatives from the
Athletics Federation of India (AFI) to submit to a “routine doping test,” so the
AFI could create a “high performance profile” for her.40 Unbeknownst to
Chand, the real reason for this testing was to investigate claims that cast into
doubt her biological gender.41 In August of that same year, Chand was notified
by the AFI that her androgen levels exceeded the allowable limited established
by the IAAF’s then-existing regulations relating to athletes with
hyperandrogenism, the IAAF Regulations Governing Eligibility of Females
with Hyperandrogenism to Compete in Women’s Competition
(Hyperandrogenism Regulations).42 Chand would successfully challenge those
regulations in 2014 in Chand v. AFI & IAAF, as discussed in Section C below.43
B. Hyperandrogenism
The term “hyperandrogenism” denotes a person who has excessive
levels of androgens.44 Androgens are a broad category of hormones that
trigger and control muscle development and sexual development.45
36

Susan Ninan, Dutee Chand, the Dreamer Who Fought the Good Fight, ESPN (Dec. 27, 2019),
https://www.espn.com/athletics/story/_/id/28371078/dutee-chand-dreamer-fought-good-fight.
37
Mike Ives, Sprinter Dutee Chand Becomes India’s First Openly Gay Athlete, N.Y. TIMES (May
20, 2019), https://www.nytimes.com/2019/05/20/world/asia/india-dutee-chand-gay.html; Amrit Dhillon,
‘No One Can Live Without Love’: Athlete Dutee Chand, India’s LGBT Trailblazer, GUARDIAN (June 10,
2019, 12:08 AM), https://www.theguardian.com/world/2019/jun/10/no-one-can-live-without-loveathlete-dutee-chand-indias-lgbt-trailblazer.
38
Chand v. Athletics Fed’n of India (AFI) & The Int’l Ass’n of Athletics Fed’ns (IAAF), CAS
2014/A/3759, para. 1 (Court of Arbitration for Sport, 2015); see also Ninan, supra note 36 (discussing
Chand’s gold medal sweep in the 100m, 200m, and 400m at the 2013 Indian National School Games).
39
Chand, CAS 2014/A/3759 para. 1.
40
Id. para. 11.
41
Id. para. 13. In a letter from the AFI to the SAI, the Secretary of the AFI stated, “[i]t has been
brought to the notice of the undersigned that there are definite doubts regarding the gender of an Athlete
Ms. Dutee Chand.” Id.
42
Id. paras. 4, 16.
43
Id. paras. 547–48.
44
Bulent O. Yildiz, Diagnosis of Hyperandrogenism: Clinical Criteria, 20 BEST PRAC. & RSCH.
CLINICAL ENDOCRINOLOGY & METABOLISM 167, 167 (2006).
45
Carrie J. Bagatelli & William J. Bremner, Androgens in Men – Uses and Abuses, 334 DRUG
THERAPY 707, 707–08 (1996).
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46

Testosterone is just one kind of androgen. Thus, a woman with
hyperandrogenism produces more androgens, usually testosterone, than
other women.47 In some situations, hyperandrogenism can be present from
birth, since “[a] few women are born with differences (or disorders) of sex
development (DSD) in which the development of chromosomal, gonadal,
and anatomic sex is atypical.”48 In other cases, hyperandrogenism can be
caused by the interaction of genetic and environmental factors.49
The most common medical condition that causes hyperandrogenism is
polycystic ovary syndrome (“PCOS”), a hormonal disorder that may cause
a woman’s ovaries to accumulate fluid and release eggs irregularly.50 PCOS
affects between five and ten percent of women worldwide, meaning that a
considerable portion of all women could be classified as having
hyperandrogenism, like Semenya and Chand, were they to be subjected to
the same scrutiny.51 In addition to PCOS, a wide variety of medical
conditions can result in hyperandrogenism, such as congenital adrenal
hyperplasia and partial androgen insensitivity syndrome.52
Rather than distinguishing between the different specific causes of
hyperandrogenism, the IAAF’s regulations take a more straightforward
approach and establish maximum testosterone levels that female athletes
cannot exceed. The first iteration of the regulations, the Hyperandrogenism
Regulations, set a threshold of ten nanomoles of testosterone per liter of
blood (“nmol/L”).53 The most recent version of the regulations, the 2018
Eligibility Regulations for the Female Classification (Athletes with
Differences of Sex Development) (the “DSD Regulations”), lowered that
threshold to five nmol/L.54 “Most women,” in contrast, “including elite
female athletes, have natural testosterone levels of 0.12 to 1.79 nanomoles
per liter.”55 Chand and Semenya’s respective testosterone levels have not
been publicly disclosed, due in large part to efforts by the athletes to preserve

46

Id.
Rebecca M. Jordan-Young, Peter H. Sönksen & Katrina Karkazis, Sex, Health, and Athletes, 348
BMJ 1, 1–2 (2014).
48
Angelica Lindén Hirschberg, Hyperandrogenism in Female Athletes, 104 J. CLINICAL
ENDOCRINOLOGY & METABOLISM 503, 503 (2019).
49
Jordan-Young et al., supra note 47, at 1–2.
50
Robert L. Barbieri & David A. Ehrmann, Diagnosis of Polycystic Ovary Syndrome in Adults,
UPTODATE (Aug. 25, 2020), https://www.uptodate.com/contents/diagnosis-of-polycystic-ovary-sy
ndrome-in-adults; Polycystic Ovary Syndrome (PCOS), MAYO CLINIC, https://www.mayoclinic.org/dis
eases-conditions/pcos/symptoms-causes/syc-20353439 (last visited Feb. 18, 2021).
51
Barbieri & Ehrmann, supra note 50.
52
See DSD Regulations, supra note 13, § 2.2(a) (listing various sexual development disorders that
can lead to hyperandrogenism).
53
Hyperandrogenism Regulations, supra note 13, § 6.5.
54
DSD Regulations, supra note 13, § 2.2(a)(iii).
55
Jeré Longman & Juliet Macur, Caster Semenya Loses Case to Compete as a Woman in All Races,
N.Y. Times (May 1, 2019), https://www.nytimes.com/2019/05/01/sports/caster-semenya-loses.html.
47
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their privacy, although the IAAF has made clear that they have exceeded the
allowable limits.56
Many of the aforementioned medical conditions that cause
hyperandrogenism can pose serious health risks to those afflicted. For
example, polycystic ovary syndrome can lead to infertility, miscarriage,
diabetes, or cardiovascular risks.57 Despite these types of serious health
effects, the IAAF considers hyperandrogenism to offer a competitive
advantage: “The difference in athletic performance between males and
females is known to be predominantly due to higher levels of androgenic
hormones in males resulting in increased strength and muscle development.”58
C. Hyperandrogenism & Anti-Doping Regulations
Since the initial controversy over Semenya’s presence in IAAF events
in 2009, the IAAF has gone through several iterations of rules and
regulations that dictate the ways by which intersex athletes can compete in
IAAF-sanctioned events. The two most recent iterations of those regulations
will be analyzed here. They are the aforementioned Hyperandrogenism
Regulations, which were enacted in 2011,59 and the 2018 DSD
Regulations.60 Both were the central focus in the cases brought before the
Court of Arbitration for Sport by Semenya and Chand.61
1. Anti-Doping Regulations
Regulation of athletes with hyperandrogenism is closely related to
anti-doping regulations, which have already been in place for many years.
In contrast to hyperandrogenism, which is a category of genetic conditions
that the athletes are born with, there is a litany of performance-enhancing
drugs that athletes can voluntarily ingest in order to gain a competitive

56
See Chand v. Athletics Fed’n of India (AFI) & The Int’l Ass’n of Athletics Fed’ns (IAAF), CAS
2014/A/3759, paras. 341–43 (Court of Arbitration for Sport, 2015) (recounting testimony by Nick
Davies, IAAF Communications Director, in which he explained why he chose to leak to the press news
of Semenya’s gender verification testing prior to the 800m final at the 2009 world championships); see
also Raheel Saleem, The Olympic Meddle: The International Olympic Committee’s Intrusion of Athletes’
Privacy Through the Discriminatory Practice of Gender Verification Testing, 28 J. MARSHALL J.
COMPUT. & INFO. L. 49, 50–51 (2010) (critiquing the use of gender verification testing by the IAAF and
the International Olympic Committee due to invasiveness and lack of scientific reliability); Annie Bach
Yen Nguyen, Fairness at a Price: Protecting the Integrity of Athletic Competitions at the Expense of
Female Athletes, 8 NOTRE DAME J. INT’L & COMP. L. 54, 56 (2018) (discussing gender verification
testing, in particular the justification for its use to ensure fair competition).
57
Barbieri & Ehrmann, supra note 50.
58
Hyperandrogenism Regulations, supra note 13, at 1.
59
Francisco J. Sánchez, María José Martinez-Patiño & Eric Vilain, The New Policy on
Hyperandrogenism in Elite Female Athletes Is Not About “Sex Testing”, 50 J. SEX RES. 112, 112–13
(2013).
60
DSD Regulations, supra note 13, § 1.1.
61
Chand, CAS 2014/A/3759 para. 4 (Court of Arbitration for Sport, 2015); Semenya v. Int’l Ass’n
of Athletics Fed’ns, CAS 2018/O/5794 paras. 1–2 (Court of Arbitration for Sport, 2018).
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62

advantage. The IAAF, like virtually all professional sporting bodies, has
strict rules prohibiting performance-enhancing drugs.63 In addition, the
World Anti-Doping Agency (“WADA”) oversees and coordinates
international anti-doping efforts under the World Anti-Doping Program
(“WADP”).64 The WADP makes clear that its purpose is to preserve the
integrity of the sport and prevent cheating through the use of
performance-enhancing drugs. “The purposes of the WADP are: [t]o protect
the Athletes’ fundamental right to participate in doping-free sport and thus
promote health, fairness and equality for Athletes worldwide. . . .”65
Hyperandrogenism is related to performance-enhancing drugs in that both
result in athletes competing with higher levels of hormones that can lead to
greater muscle development and other such competitive advantages. As
such, it comes as no surprise that the following regulations the IAAF enacted
in the past decade were structured similarly to anti-doping regulations.
2. Hyperandrogenism Regulations
After Semenya’s controversial success at the 2009 World
Championships, the IAAF set out to regulate the participation of female
athletes with hyperandrogenism in track and field events.66 A committee was
convened in 2010, and by 2011 it published the Hyperandrogenism
Regulations. These regulations “establish[ed] a framework for the
determination of the eligibility of females with hyperandrogenism to
participate in International Competitions.”67 The regulations had a three-tier
structure with varying degrees of testing and examination of the particular
athlete, ranging from an “Initial Clinical Examination,” to a “Preliminary
Endocrine Assessment,” and a full examination.68
62
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Approaches of FIFA and the IAAF to Doping in Sport, 11 EUR. SPORT MGMT. Q. 445, 455 (2011); see
also Book of Rules, WORLD ATHLETICS, https://www.worldathletics.org/about-iaaf/documents/book-ofrules (last visited Jan. 6, 2021) (containing the IAAF’s anti-doping rules and regulations).
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Weston, supra note 62, at 24.
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https://www.wada-ama.org/sites/default/files/resources/files/wada_anti-doping_code_2009_en_0.pd
f); see also Michael S. Straubel, Doping Due Process: A Critique of the Doping Control Process in
International Sport, 106 DICK. L. REV. 523, 531 (2002) (raising due process concerns regarding
anti-doping policies that can be detrimental to athletes’ careers if they have a false positive and are unable
to effectively appeal any punishment they receive).
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7:43 AM), https://www.theguardian.com/sport/2011/apr/12/iaaf-athletics-rules-hyperandrogenismcaster-semenya.
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Hyperandrogenism Regulations, supra note 13, § 1.1.
68
Id. § 5.1. The IAAF and IOC have been roundly criticized for the invasiveness of gender
verification testing involved in these recent regulations, as well as over many decades. For a historical
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The initial investigatory process could be initiated in two ways. First, a
female athlete who was already aware that she had hyperandrogenism was
required to notify the IAAF of her status.69 In the alternative, an IAAF
official known as the Medical Manager was vested with the power to
investigate athletes suspected of having hyperandrogenism, by “initiat[ing]
a confidential investigation of any female athlete if he has reasonable
grounds for believing that a case of hyperandrogenism may exist.” 70 The
“reasonable grounds” by which this investigation could be initiated were
far-ranging. They could include the results of a previous anti-doping test, or,
much more broadly, a confidential tip from any source, “information
received by the IAAF . . . or other responsible medical official at a
competition.”71 In either case, the three-tier testing procedures would follow.
Depending on the particular facts of the athlete’s case, either Level 1 or
Level 2 testing would begin. Level 1 testing involved a basic medical
examination of the athlete known as an “Initial Clinical Examination.”72 In
almost all cases, a Level 1 examination would occur prior to a Level 2
Preliminary Endocrine Assessment.73 If the athlete was asked to undergo
Level 2 testing, then they would provide urine and blood samples for testing.74
Following testing under either Level 1 or 2, the IAAF Medical Manager
would review the results and determine whether the athlete’s case should be
referred to an Expert Medical Panel.75 In that case, the Expert Medical Panel,
which was comprised of experienced medical professionals within the
IAAF, would review all medical results and determine if “a full examination
and diagnosis [was] required under Level 3.”76 If Level 3 testing was
ordered, then the athlete would “submit to a full examination at an
IAAF-approved specialist reference centre so that a final and precise
diagnosis of the athlete whenever possible [could] be carried out.”77 These
results were then transmitted back to the Expert Medical Panel for a final
determination of the athlete’s eligibility to compete.78 The Expert Medical
Panel’s final determination would be based almost entirely on a
determination of whether or not the athlete’s testosterone levels exceeded
the maximum range established by the regulations.79 That threshold was ten
nanomoles per liter of blood.80 The language of the regulations was such that
the Panel had little discretion to permit an athlete to compete if she exceeded
69
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71
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that level, stating that “[t]he Expert Medical Panel shall recommend that the
athlete is eligible to compete in women’s competition if . . . she has androgen
levels below the normal male range.”81 In the case that the athlete exceeded
that level, the Panel was directed to describe conditions under which the
athlete could return to competition after undergoing hormone suppression
treatment.82 These Hyperandrogenism Regulations were eventually struck
down in Chand v. IAAF due to a lack of scientific evidentiary support to
establish the ten nanomole per liter threshold,83 as discussed in Part II.
3. DSD Regulations
In November 2018, the IAAF enacted the DSD Regulations. 84 These
largely mimic the Hyperandrogenism Regulations in terms of the process for
IAAF officials initiating an investigation and the resulting testing procedures
of athletes suspected to have excessive testosterone levels.85 However, the
DSD Regulations differ from the Hyperandrogenism Regulations in several
important ways. Furthermore, these differences reflect the arbitration
panel’s criticism of the Hyperandrogenism Regulations (to be discussed in
Section II).
First and foremost, the DSD Regulations are more targeted both in terms
of the athletes and the events that are impacted. In recognition of the wide
range of conditions that can lead to hyperandrogenism, the regulations affect
only those athletes with differences of sexual development (“DSD”). This
term refers to “congenital conditions that cause atypical development of [the
athlete’s] chromosomal, gonadal, and/or anatomic sex.”86 Thus, the new
regulations exclude other conditions, such as PCOS, that can also cause
hyperandrogenism.87 Those athletes with a DSD are considered “Relevant
Athlete[s],” as determined by criteria laid out in section 2.2(a).88
In addition to applying only to athletes with a DSD, these new
regulations also only apply to certain “Restricted Events.” 89 That term
covers the events ranging in distance from 400 meters to one mile.90 If a
Relevant Athlete wishes to compete in a Restricted Event, then she is subject
to the “Eligibility Conditions” set forth in section 2.3.91 The most important
81
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of these conditions is that the athlete must have a blood testosterone level
below five nanomoles per liter.92 If she exceeds that amount, then she must
reduce and maintain her blood testosterone level below that threshold for a
period of six months before returning to competition and in perpetuity
thereafter.93 Those athletes who choose not to take medication to reduce their
testosterone levels will still be eligible to compete in non-international
competitions or in international IAAF-sanctioned competitions, but not in
the Restricted Events.94 Semenya, like Chand, challenged the validity of
these regulations.95 However, the DSD Regulations were upheld96 for
reasons discussed in Part II.
D. Court of Arbitration for Sport
Chand and Semenya’s respective challenges to the Hyperandrogenism
and DSD Regulations were heard by the Court of Arbitration for Sport
(“CAS”). The CAS provides various dispute resolution services, such as
arbitration panels that “facilitate the settlement of sports-related disputes
through arbitration or mediation by means of procedural rules adapted to the
specific needs of the sports world.”97 The CAS was originally established by
the International Olympic Committee (“IOC”) in 1984, but has since become
the venue for dispute resolution for a wide range of international sports and
issues that transcend individual sports, such as the use of
performance-enhancing drugs.98 The work of the CAS is “divided into
Ordinary and Appellate divisions.”99 Regardless of the division, matters
before the CAS are heard by a panel of members selected to serve as
independent arbitrators.100 The parties to the matter are permitted to select
the arbitrators that will hear their case from a list provided by CAS. 101
Additionally, the parties can select the substantive law that will be applied
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to their case, although the procedure of the arbitration follows CAS code.102
The Ordinary Division acts as a trial court and hears matters that have
initially been filed with the CAS. 103 The Appellate Division, in contrast,
serves an appellate function similar to that of the circuit courts in the United
States. This division “handle[s] appeals from the decisions of sports
federations, associations, or sports-related bodies.”104
II. ANALYSIS
A. Deficiencies of IAAF Policies for Intersex Athletes
Prior to assessing the reasons for the different outcomes in the cases
brought by Chand and Semenya, it is necessary to interrogate the
justifications the IAAF has provided for all of its hyperandrogenism
regulations. The IAAF has consistently relied on a two-part justification for
its regulations. First, it has claimed they are necessary in order to preserve
the fairness and integrity of the sport.105 Second, it has alleged that there is
sufficient scientific evidence indicating that increased testosterone levels
confer a competitive advantage.106 According to the IAAF, the competitive
advantage conferred by hyperandrogenism is simply too significant, since
“[t]o the best of [the IAAF’s] knowledge, there is no other genetic or
biological trait encountered in female athletics that confers such a huge
performance advantage.”107 These justifications both implicitly and
explicitly make use of the inherent need to divide competitors based on sex.
However, they also have several important shortcomings that can be
instructive in formulating new, more inclusive policies.
1. Claims of the Need to Preserve Fair Competition
Throughout both the Hyperandrogenism and DSD Regulations, as well
as in briefs submitted to the CAS in defense of those regulations, the IAAF
repeatedly emphasized the need to uphold the clear distinction between the
male and female categories for the sake of preserving the fairness of the
sport. The introduction of the DSD Regulations plainly states, “The IAAF
wants athletes to be incentivised to make the huge commitment and sacrifice
required to excel in the sport . . . . It does not want to risk discouraging those
aspirations by having unfair competition conditions that deny athletes a fair
opportunity to succeed.”108 The Preface to the Hyperandrogenism
Regulations made a similarly explicit reference to the underlying principles
102
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of “[a] respect for the very essence of the male and female classifications in
Athletics,” as well as “[a] respect for the fundamental notion of fairness of
competition in female Athletics.”109
In light of this need for fairness, the IAAF portrayed hyperandrogenism
and related conditions as conferring such a competitive advantage that they
threatened to fundamentally undermine the fairness of the sport. This was
especially true in the DSD Regulations. In explanatory notes accompanying
those regulations when they were released to the public on May 1, 2019, the
IAAF stated that female athletes competing with elevated testosterone levels
would have a roughly nine percent competitive advantage compared to their
competitors that have normal levels of testosterone.110 It is not entirely clear
where this degree of a competitive advantage was calculated from. As will be
discussed in the next section, even the IAAF’s own study on the competitive
advantage conferred by hyperandrogenism did not arrive at this value.111
2. Scientific Justifications for the Regulations
In its defenses of both the Hyperandrogenism and the DSD Regulations,
the IAAF fully acknowledged that it was impossible to pinpoint exactly the
degree to which excess testosterone due to hyperandrogenism would provide
a competitive advantage.112 Nonetheless, it justified the testosterone
thresholds of the respective regulations as being defensible because there
was some degree of a competitive advantage, even if that exact degree of
advantage was indeterminable.113
The central number in the Hyperandrogenism Regulations was the ten
nmol/L testosterone threshold.114 Rather than conducting its own analysis of
elite female athletes to reach that particular number, the IAAF merely
referenced the broad scientific consensus of what were considered the
permissible ranges for male and female athletes.115 At the time that the
Hyperandrogenism Regulations were enacted, the IAAF posited that
“established endocrinology textbooks” generally agreed that the lower limit
of average testosterone levels in males was 6.9 nmol/L.116 By comparison,
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the ten nmol/L threshold of the Hyperandrogenism Regulations appeared
“more liberal” and, thus, more palatable.117
The IAAF made this appeal to having a generally liberal standard
because, as it fully acknowledged, it was not possible to determine the
precise degree of competitive advantage conferred by hyperandrogenism:
“[the IAAF] acknowledged that there may be other contributing factors to
the difference in athletic performance between men and women.”118 The
scientific evidence was still justifiable, it claimed, because “no other known
factors show such a clear-cut difference between women and men,” and
“testosterone remains the most suitable differentiating factor.”119 This
reasoning is flawed. Determining that testosterone is merely an important
factor in athletic performance is not equivalent to determining precisely how
much it impacts athletic performance, and whether that impact is
impermissibly significant.
Fortunately, the CAS struck down the Hyperandrogenism Regulations
largely based on their scientific deficiencies. It found “the IAAF was unable
to demonstrate with scientific certainty that there is no difference between
the effects of endogenous [internally-produced] and exogenous
[externally-provided] testosterone on athletic performance.”120 In other
words, the panel found “insufficient evidence about the degree of the
advantage.”121 The CAS charged the IAAF to gather more evidence to justify
this type of discriminatory regulation. Such evidence would more
conclusively establish the “quantitative relationship between enhanced
testosterone levels and improved athletic performance in hyperandrogenic
athletes.”122 In the meantime, the CAS panel suspended the testosterone rule
for two years.123 The result of that evidence gathering would be the DSD
Regulations that Caster Semenya challenged in 2019.
The IAAF responded to the CAS ruling in Chand by seeking out more
targeted data by looking inward to its own athletes. 124 With the rise of
anti-doping policies over the past decade, the IAAF began drug testing
athletes a regular basis.125 This enabled the IAAF to compile an extensive
117
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body of data on virtually all competitors at recent international competitions.
It then used this data to conduct a study that would form a stronger scientific
basis for revised regulations for intersex athletes.126
That study, published in 2017 by Stéphane Bermon and Pierre-Yves
Garnier, two medical researchers affiliated with the IAAF, analyzed the
androgen levels of a total of 2,127 athletes that competed at the 2011 IAAF
World Championships in Daegu, South Korea, and the 2013 IAAF World
Championships in Moscow, Russia.127 The study grouped the athletes by the
event they competed in and their single best performance in that event.128
Those performances were then compared to the androgen levels present in
the blood samples that they provided at the beginning of the competition.129
The study found that twenty-four athletes had testosterone levels above 3.08
nmol/L.130 Of those twenty-four, nine were later discovered to be using
performance-enhancing drugs, while another nine were diagnosed with
having hyperandrogenism.131 More importantly, the study found that in
certain events, female athletes with elevated testosterone levels enjoyed a
statistically significant competitive advantage “[i]n female 400 m, 400 m
hurdles, 800 m, hammer throw and pole vault, high [testosterone]
concentration is associated with a higher (from 1.8% to 4.5%) level of
athletic performance when compared with competitors with low
[testosterone].”132 It was upon the results of this study that the IAAF based
the DSD Regulations.
Despite this more targeted basis, the DSD Regulations still cannot
establish the precise degree of competitive advantage conferred on athletes
with hyperandrogenism. Bermon and Garnier admit as much: “Our study
design cannot provide evidence for causality between androgen levels and
athletic performance, but can indicate associations between androgen
concentrations and athletic performance.”133 Hence, the IAAF responded to
the CAS panel’s charge in Chand to provide scientific evidence of a stronger
link between elevated testosterone levels and athletic performance by
constructing a study that, although more targeted and based on data from
current elite athletes, was still only able to demonstrate mere “associations”
between testosterone levels and athletic performance.134 Herein lies the
shortcoming of any attempt to justify regulations on athletes with
hyperandrogenism through science-based arguments: the process of training
to become a world-class athlete involves an incalculable number of different
126
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factors. Each athlete has a different diet, training plan, injury history, and
genetic makeup. Regardless of a respective athlete’s testosterone levels,
their athletic achievement is dependent on the combination of a host of
factors, one of which happens to be their hormonal composition.
Ultimately, the overstated importance of the testosterone threshold is
made evident by the fact that both Chand and Semenya were not deemed
ineligible because their precise testosterone levels exceeded the allowable
limit. Chand only underwent preliminary testing conducted by the AFI, but
did not submit to the three-stage process of medical examination dictated by
the Hyperandrogenism Regulations.135 Based on her refusal, the IAAF and
AFI assumed that her testosterone levels exceeded the 10nmol/L threshold
without actually testing her.136 Similarly, Semenya did not undergo the
examination required by the DSD Regulations.137 She had already filed her
initial challenge of the regulations with the CAS on June 18, 2018, nearly
five months before the regulations officially went into effect on November
1, 2018.138 Analyzing the scientific underpinnings of the IAAF’s various
regulations for intersex athletes reveals the inherent impossibility of
demonstrating just how much of a competitive advantage hyperandrogenism
provides athletes. The fact that hyperandrogenism conflicts with the basic
male/female division of the sport consequently leads governing and
adjudicatory bodies to uphold the regulations and jeopardize the careers of
promising young athletes.
B. Deficiencies of Legal Reasoning Upholding IAAF Policies
In spite of the scientific shortcomings of the different iterations of the
regulations, the true legal deficiencies of the regulations lay in their
discriminatory nature. In both cases brought by Chand and Semenya, the
CAS employed a two-part legal analysis. The initial burden was on the
athlete to prove that the regulations were discriminatory.139 Upon
establishing the initial burden, the question then became whether the
regulations were necessary, reasonable, and proportionate to justify the
discriminatory effect on intersex athletes.140 At that time, the burden shifted
to the IAAF.141 In Chand, the IAAF conceded, and the CAS accepted, that
the regulations at issue were prima facie discriminatory, whereas in
Semenya, the IAAF defended the DSD regulations as nondiscriminatory but
135
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the CAS nonetheless determined that Semenya had established a case that
the regulations were prima facie discriminatory.142 The more salient issue,
particularly in Semenya, was whether the regulations were necessary,
reasonable, and proportionate and thus justified in their discriminatory impact.
1. Semenya v. IAAF
The CAS panel focused primarily on the proportionality of the DSD
Regulations to determine whether they were necessary and reasonable,
noting that “the criterion for reasonableness is whether the restrictions
imposed by the DSD Regulations are rationally connected to their objective
of ensuring fair competition for female athletes in elite athletics.”143 To
prove this rational and proportionate connection, the IAAF once again
asserted its obligation to ensure fair competition. It characterized the DSD
Regulations as “‘an extremely progressive and fair compromise’ between . .
. the right of female athletes to compete separately from men so that they
have the same opportunity to excel, and . . . the desire of ‘certain biologically
male athletes with female gender identities’ to compete in the female
category of competition.”144 In particular, it pointed to the fact that the DSD
Regulations applied only to the Restricted Events. The IAAF claimed that
the regulations were targeted to apply only to those events in which there
was a statistically demonstrated competitive advantage.145 Thus, this
constituted a rational connection between the threat of athletes with
hyperandrogenism having a competitive advantage, and the solution of
preventing them from competing in events in which that advantage would
be particularly high. The CAS panel agreed with this argument, explaining
that “the Regulations do not apply to all events but only to those Restricted
Events for which evidence is relied on to demonstrate a practical performance
advantage.”146 Therefore, the panel found the regulations, as applied to
Relevant Athletes competing in Restricted Events, to be necessary based on
the scientific evidence compiled in the Bermon and Garnier study.147
The CAS panel appears to have upheld the regulations because it
implicitly adopted the IAAF’s reasoning that the significant impact on a few
athletes, namely Caster Semenya, was justified for the broader purpose of
preserving the crucial male-female competition distinction within the sport
as a whole. Closer scrutiny of the CAS’s implicitly biased reasoning reveals
this balancing decision. For example, the Restricted Events in the DSD
Regulations do not perfectly mirror the events that the Bermon and Garnier
study deemed most apt to provide significant competitive advantages to
142
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athletes with hyperandrogenism. Rather, the Restricted Events appear to
specifically target Semenya, in direct contradiction of the study’s results.
The Restricted Events range from the 400 meters to the one mile 148—
the races in which a middle distance runner like Semenya competes.149 The
Regulations themselves allude to this possible targeting, particularly in §
1.1(d): “These Regulations accordingly permit such [intersex] athletes to
compete in the female classification in the events that currently appear to be
most clearly affected only if they meet the Eligibility Conditions . . . .” 150
The Bermon and Garnier study did not conclude that exact range of events
was most prone to providing a competitive advantage to athletes with
hyperandrogenism. Rather, it identified other events—hammer throw and
pole vault—in which athletes with hyperandrogenism would have a
significant competitive advantage.151 The only noticeable difference between
events like the 400m and 800m races and field events like hammer throw
and pole vault is that those field events were not being dominated by famous
(or infamous) hyperandrogenous athletes. Similarly, the CAS expressed
misgivings about the inclusion of the mile and the 1500 meter run as
Restricted Events due to “a speculative assumption that since female athletes
who compete successfully in the 800m often also compete successfully in
those longer events . . . [and those] athletes are likely to enjoy a significant
performance advantage over other female athletes in those two events.”152
The Regulations were nonetheless upheld as proportionate “in toto.”153 Thus,
the CAS fully identified that the IAAF had formulated the DSD Regulations
specifically for the purpose of preventing Caster Semenya from continuing to
compete in IAAF competitions, yet still determined that the regulations were
necessary, reasonable, and proportionate. This outcome can be attributed to
the structural obstacle with which intersex athletes must contend.
The CAS is an international body of arbitration that focuses broadly on
matters affecting entire sporting organizations or even countries. Its focus is
thus similar to that of the IAAF: ensure as much inclusiveness as possible
while prioritizing the perceived fairness of the sport of track and field so that it
can continue in perpetuity. If the CAS ruled that the targeted DSD Regulations
were unreasonable, unnecessary, and disproportionate, then that would have
created an even greater problem that the IAAF would have had to confront.
By ruling as it did, the CAS ensured administrative ease for the IAAF and a
just outcome for the majority of athletes, all of whom are not intersex.
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C. Policy Considerations of the Applicability of American Equal
Protection Law
1. Title VII
The fundamental difficulty of enacting regulations that are both
inclusive and ensure fairness of the sport is that hyperandrogenism and other
such intersex conditions conflict with the fundamental division of the sport:
biological males competing against biological males and biological females
competing against biological females. This fundamental obstacle for athletes
like Semenya implicitly justifies their discriminatory treatment. Even in the
context of American equal protection jurisprudence, the same fundamental
obstacle would persist.
Semenya’s challenge to the DSD Regulations bears many similarities to
a discrimination claim that would be filed in an American court. Semenya
herself used traditional equal protection language in her arguments against
the DSD Regulations: “the DSD Regulations unfairly discriminate against
athletes on the basis of sex and/or gender because they only apply (i) to
female athletes; and (ii) to female athletes having certain physiological
traits.”154 Semenya alleged that the regulations were discriminatory, based
on no sound scientific basis, and disproportionate in their impact on certain
athletes.155 According to Semenya, the regulations placed restrictions on
athletes who had not undertaken any actions in order to gain a supposed
competitive advantage: “The Regulations restrict the ability of some female
athletes to compete based solely on a natural or genetic trait which they have
possessed since birth and over which they have no control.”156 The
regulations were therefore patent sex discrimination: “The Regulations
impose thresholds and burdens (such as screening for high testosterone,
invasive medical examinations, and eligibility restrictions) on female
athletes, while no equivalent requirements are applied to male athletes.”157
Although the claim mirrors a sex discrimination claim, if Semenya filed
it under Title VII of the Civil Rights Act of 1964 in an American court,158
she would still encounter the same structural issue. Title VII applies in the
employment context and prohibits disparate treatment and disparate impact
on the basis of “race, color, religion, sex, or national origin.” 159 The statute
is an especially powerful tool in the employment context for preventing sex
discrimination.160 The problem that Semenya would encounter, though, is
that Title VII is also structured on the basic distinction between male and
154
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161

female categories. This is because the adjudicatory process for a Title VII
claim, under either disparate impact or disparate treatment analysis, is that
of comparing the two categories of genders:
Whether the discrimination is demonstrated in the treatment or
in its impact, Title VII doctrine requires comparison of groups
in order to show discrimination. The intent of the employer is
irrelevant; it is the comparison that matters. In sex
discrimination cases, this focus on comparison means one
thing: the comparison of men and women. In order to
determine whether employment discrimination “because of . .
. sex” has occurred, courts ask “whether or not men and
women were treated differently,” and “whether similarly
situated and similarly available men and women have been
treated differently from each other.”162
A similar logic persists in the CAS analysis. Without a clearly
discernible category in which to place intersex individuals, it was not clear
which protections, if any, were necessary for people who could not be
categorized.163 In the face of this ambiguity, the IAAF’s countervailing
argument to preserve fair play and equal competition, bolstered by
tangentially applicable scientific research, was sufficiently strong to pass
judicial muster.164
In fact, rather than increasing Semenya’s chances of winning her legal
claim, American equal protection law would very likely lead to the opposite
outcome. The IAAF seemingly emulated American equal protection
jurisprudence when it enacted the DSD Regulations by classifying female
athletes as “a protected class.”165 Doing so enabled the IAAF to draw
parallels between the need for equal opportunities for female and male
athletes.166 It portrayed the DSD Regulations as “a progressive and fair
compromise” between enabling female athletes to “have a separate category
of competition from the men so that they have the same chances to excel,”
while, at the same time, providing an opportunity for “certain biologically
male athletes with female gender identities to compete in the female
category of competition” by undergoing hormone therapy.167
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2. Title IX
Semenya would also likely lose if she were to file a Title IX claim.168
Enacted as part of the Education Amendments of 1972, Title IX was
intended to “remedy to some extent sex discrimination in education” by
requiring equality of sporting and educational opportunities for male and
female students.169 In the ensuing forty years since its enactment, the law
has, among other achievements, led to millions of girls having the
opportunity to play competitive sports in both high school and college.170 In
addition, Title IX has increasingly been used to provide transgender
student-athletes an equal opportunity to participate in high school sports.171
This was the case for two high school students in Connecticut, Andraya
Yearwood of Cromwell High School and Terry Miller of Bloomfield High
School.172 Following a change of policy by the Connecticut Interscholastic
Athletic Conference to allow transgender students to immediately begin
competing in conformity with their gender identity, Yearwood and Miller
began competing as females in the 2016-17 school year.173 Since then, the
two have won numerous state championships in indoor and outdoor track
and field in running events ranging from 55 to 300 meter distances.174 These
athletes, like Caster Semenya, have faced considerable criticism from those
who claim that their transgender status gives them a competitive
advantage.175 This criticism culminated in June 2019 when the Alliance
Defending Freedom filed a Title IX complaint with the U.S. Department of
Education on behalf of three Connecticut high school students. 176 This
complaint is noteworthy because it makes virtually the same argument that
168
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professional athletes such as Semenya and Chand have made, yet it
advocates for the opposite outcome.
Each of the three complainants are cis-gendered females who competed
against Miller and Yearwood.177 According to the complaint, their goals for
participating in track and field were to experience the joy of success, and to
possibly succeed to such an extent that they would receive scholarship offers
and compete at the collegiate level.178 Unfortunately, the complaint
continues, the aspirations of these athletes are being jeopardized due to the
CIAC’s policy that “is permitting boys who are male in every biological and
physiological respect—including unaltered male hormone levels and
musculature—to compete in girls’ athletic competitions if they claim a
female gender identity.”179 The complaint goes on, much like the IAAF, to
provide ample evidence supporting the basic notion that there are inherent
physiological differences between males and females—particularly in high
school when individuals are undergoing puberty at varying rates—which
leads to competitive advantages.180 For example, the complaint presented
the results of state championship meets during the years Miller and
Yearwood were competing. In pointing to the results, it explicitly claimed
that the presence of transgender athletes deprived “specific, identifiable girls
. . . the recognition of being named state-level first-place champions, and/or
. . . the opportunity to advance and participate in higher-level competition.”181
This deprivation of opportunity was due entirely to unfair physiological
differences. This fact-based argument is the Bermon and Garnier study in
microcosm: a large set of results from competition are analyzed in
comparison to those few athletes who, for whatever reason, are competing
with elevated testosterone levels and could very well be succeeding for
reasons only minimally related to their testosterone levels.182
The complainants alleged that this policy was in violation of Title IX
because it was resulting in more boys than girls “experiencing victory and
gaining the advantages that follow,” even though competition is supposed to
“ensure that equal numbers of boys and girls advance to higher levels of
competition.”183 Citing McCormick ex rel McCormick v. School District of
Mamaroneck, the complaint alleged that this policy was patently in violation
of Title IX: “[t]reating girls differently regarding a matter so fundamental to
the experience of sports—the chance to be champions—is inconsistent with
Title IX’s mandate of equal opportunity for both sexes.”184 Here again, the
177
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structural division of track and field is being used to the detriment of certain
athletes—in this case, transgender individuals. Thus, if Semenya were to
bring suit under Title IX and challenge the DSD Regulations, she would
likely face similar counterclaims that, per Title IX, her presence on the track
was in fact depriving cis-gendered females of the opportunity to compete
and succeed.
CONCLUSION
Track and field is perhaps the purest form of competition—there is never
any doubt as to who the victor is. It will be the person who ran the fastest,
jumped the highest, or threw the farthest. It therefore comes as no surprise
that a sport dealing in such absolutes would have particular difficulty
resolving issues that are anything but black and white. Intersex and
transgender athletes have every right to compete in the sport, yet they are
being prevented from doing so by the inherent nature of a sport that requires
a level playing field at all costs. There is evidently no clear solution to this
intractable issue at present. Regardless, a complicated issue such as this will
require the sport’s governing bodies at all levels of competition to reassess
how they prioritize certain goals, evaluate the inherent inequities of the
system, and challenge policymakers to develop new rules based on sound
science.185

185
See Erin E. Buzuvis, Transgender Student-Athletes and Sex-Segregated Sport: Developing
Policies of Inclusion for Intercollegiate and Interscholastic Athletics, 21 SETON HALL J. SPORTS & ENT.
L. 1, 28–29 (2011) (describing an effective and inclusive policy for transgender student athletes as one
that incorporates law, science, and morality).

